Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07037589

Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed?

This prospective multicenter observational study evaluates whether women ≥50 years with isolated acute hemorrhagic cystitis (AHC) and macroscopic hematuria require full malignancy workup. All participants undergo standard diagnostics (cystoscopy, CT urography, cytology), with 12-month follow-up for cancer detection. The aim is to identify low-risk patients where invasive investigations may be safely avoided.

Recruiting

Interested in participating?

Request Info

Key information

About this study

The BLUSH trial is a prospective, multicenter, observational study investigating whether full malignancy workup is necessary in women ≥50 years presenting with isolated acute hemorrhagic cystitis (AHC) and macroscopic hematuria. AHC is defined as macroscopic hematuria accompanied by acute lower urinary tract symptoms (dysuria, frequency, urgency) of less than one week's duration. Women with prior urological malignancies, significant comorbidities, or impaired consent capacity are excluded.

All enrolled patients undergo standardized initial assessment including full clinical history (smoking, family history, comorbidities), physical examination, urinalysis, urine culture, cystoscopy, CT urography, and cytology when indicated. Participants are stratified into AHC and non-AHC groups based on symptomatology and laboratory findings. Data collection includes demographics, symptom duration, urine findings, cancer diagnoses (type, stage, grade), treatment details, and clinical outcomes.

Patients are followed for a minimum of 12 months via medical record review to capture delayed cancer diagnoses. Data are pseudonymized and stored securely under GDPR regulations. The primary outcome is the incidence of urological malignancy within one year. Secondary outcomes include time to diagnosis, proportion of avoidable invasive procedures, and accuracy of the AHC classification in predicting cancer risk.

The study aims to support individualized risk-based management in women with hematuria.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women ≥50 years of age.
  • Macroscopic hematuria.
  • Presenting for evaluation within the SCP for macroscopic hematuria.
  • Ability to provide informed consent.

Exclusion criteria

  • Prior diagnosis of bladder cancer, renal cancer, or upper tract urothelial carcinoma (UTUC).
  • Cognitive impairment preventing informed consent.
  • Ongoing or recent treatment for urological malignancy.
  • Serious comorbidities affecting participation or safety.
  • Pregnant women.

Treatment and study plan

investigation setting (cystoscopy + CTU + cytology)

Procedure

Observational study. All patients in this group undergo standard diagnostic evaluation including cystoscopy, CT urography, and urine cytology (if clinically indicated), performed during initial assessment for acute macroscopic hematuria.

Cystoscopy - CTU - cytology (if needed)

Procedure

All patients in this group undergo standard diagnostic evaluation including cystoscopy, CT urography, and urine cytology (if clinically indicated), performed during initial assessment for atypical or chronic presentations of macroscopic hematuria.

Primary outcomes

  1. Incidence of urological malignancy

    Time frame: At least 12 months from study inclusion.

    The proportion of women diagnosed with urological cancer (bladder, upper urinary tract, or kidney cancer) within 12 months after initial presentation of macroscopic hematuria.

Secondary outcomes

  1. Time to cancer diagnosis

    Time frame: At least 12 months from study inclusion.

    Duration from initial presentation to confirmed diagnosis of urological malignancy.

  2. Proportion of potentially avoidable invasive procedures in AHG

    Time frame: At least 12 months from study inclusion.

    Percentage of invasive diagnostic procedures (e.g., cystoscopy, CT-urography) in the Acute Hemorrhagic Cystitis Group (AHG) that could have been avoided based on study findings.

  3. Sensitivity and specificity of AHC classification

    Time frame: At least 12 months from study inclusion.

    Accuracy of the acute hemorrhagic cystitis (AHC) clinical classification in predicting urological malignancy, measured by sensitivity and specificity.

Study contacts

Contact information is provided by the study sponsor or research team.

Suleiman Abuhasanein, PhD

CONTACT

[email protected]

0104353572

Sponsors and collaborators

Lead sponsor

Vastra Gotaland Region

Other Gov

Registry information

Official study title

Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed? A Prospective Multicenter Study. BLUSH Trial

Acronym: BLUSH

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Jun 25, 2025
Registry last updated
Nov 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.